Glaucoma
Welcome,         Profile    Billing    Logout  
 89 Companies   65 Products   65 Products   50 Mechanisms of Action   831 Trials   64145 News 


«12...674675676677678679680681682683684...720721»
  • ||||||||||  Journal:  Congenital Rubella Syndrome in The African Region - Data from Sentinel Surveillance. (Pubmed Central) -  Apr 9, 2019   
    However, the limited surveillance data has yielded comparable information with other developing countries prior to introduction of rubella vaccine. As more countries introduce rubella vaccine into their immunisation programs, there is a need to ensure that all rubella outbreaks are thoroughly investigated and documented, to expand sentinel surveillance for CRS in more countries in the Region, and to complement this with retrospective record reviews for CRS cases in selected countries.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial primary completion date:  Macular Damage in Early Glaucoma and Progression (clinicaltrials.gov) -  Apr 9, 2019   
    P=N/A,  N=375, Recruiting, 
    As more countries introduce rubella vaccine into their immunisation programs, there is a need to ensure that all rubella outbreaks are thoroughly investigated and documented, to expand sentinel surveillance for CRS in more countries in the Region, and to complement this with retrospective record reviews for CRS cases in selected countries. Trial primary completion date: Dec 2018 --> Oct 2019
  • ||||||||||  Journal:  Optic Nerve Head Diagnostics with Optical Coherence Tomography (Pubmed Central) -  Apr 7, 2019   
    Optic nerve head examination using the OCT facilitates rapid diagnosis of infrequent and hard to distinguish pathological changes, as well as exact monitoring of chronic progressive diseases of the optic nerve. Correct application and evaluation of results gathered using OCT examination of the optic nerve head facilitates accurate diagnosis and correct decisions.
  • ||||||||||  Rhopressa (netarsudil) / Aerie Pharmaceuticals
    Clinical, Journal:  Netarsudil Ophthalmic Solution 0.02%: First Global Approval. (Pubmed Central) -  Apr 7, 2019   
    Phase III development in the EU and phase II development in Japan are underway for this indication. This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
  • ||||||||||  Journal:  Change of β-Zone Parapapillary Atrophy During Axial Elongation: Boramae Myopia Cohort Study Report 3. (Pubmed Central) -  Apr 7, 2019   
    Even in childhood, βBM PPA existed next to their γ-zone PPA in 11 eyes (24%), including 4 eyes that showed increase of both γ-zone and βBM portion during axial elongation. Enlargement of β-zone PPA during axial elongation was affected by the extent and direction of vascular trunk dragging, thus implicating disproportionate growth between the retina and sclera.
  • ||||||||||  Journal:  Additional thought concerning the glaucomas and systemic disease. (Pubmed Central) -  Apr 7, 2019   
    This work provided a new, safe and effective ocular glucauma medication; Timolol maleate gelatinized core liposomes, solving the main problems of ocular liposomal formulations of hydrophilic drugs. No abstract available
  • ||||||||||  Journal:  Optical Coherence Tomography Angiography and Glaucoma: A Brief Review. (Pubmed Central) -  Apr 6, 2019   
    It can also help detect early glaucoma, reach a floor effect at a more advanced disease stage than optical coherence tomography (OCT), and adds information about glaucoma patients at risk of progression. Although it has higher variability than OCT, it also promises to be useful for monitoring glaucoma by detecting progression throughout the glaucoma continuum.
  • ||||||||||  Journal:  Purtscher-like retinopathy preceding acute renal failure. (Pubmed Central) -  Apr 5, 2019   
    Purtscher-like retinopathy rarely precedes the associated systemic illness. Early diagnosis based on ophthalmic symptoms may help in the recognition and treatment of the disease, and prevent later complications.
  • ||||||||||  Clinical, Journal:  Differential expression of proteome in aqueous humor in patients with and without glaucoma. (Pubmed Central) -  Apr 5, 2019   
    In this study, an association between the use of AP and the development of ERM could not be demonstrated. In this pilot study, a quantitative difference was found in the protein expression of humor among patients with glaucoma, there being 27 proteins unique to patients with glaucomatous disease.
  • ||||||||||  Clinical, Journal:  Outcome of trabeculectomy with Ologen versus Mitomycin C: A comparative prospective study in Bangladesh. (Pubmed Central) -  Apr 5, 2019   
    In this pilot study, a quantitative difference was found in the protein expression of humor among patients with glaucoma, there being 27 proteins unique to patients with glaucomatous disease. Trabeculectomy augmented with Ologen appeared to be as successful and safe as trabeculectomy augmented with Mitomycin C, with no reported adverse reaction to Ologen.
  • ||||||||||  Review, Journal:  The nitric oxide-guanylate cyclase pathway and glaucoma. (Pubmed Central) -  Apr 5, 2019   
    Here we review evidence that supports direct targeting of GC as a novel pleiotrophic treatment for the disease, without the need for direct NO application. The identification and targeting of other factors that contribute to glaucoma would be beneficial to patients, particularly those that do not respond well to IOP-dependent interventions.
  • ||||||||||  Clinical, Journal:  Adherence to topical glaucoma medications and associated factors in Gondar University Hospital Tertiary Eye Care Center, northwest Ethiopia. (Pubmed Central) -  Apr 5, 2019   
    Male sex (adjusted odds ratio = 1.86 (95% confidence interval: 1.13-3.06)), urban residence (adjusted odds ratio = 2.33 (95% confidence interval: 1.46-3.72)), normal visual acuity (adjusted odds ratio = 2.23 (95% confidence interval: 1.13-4.42)), low visual acuity (adjusted odds ratio = 1.74 (95% confidence interval: 1.05-2.88)), and self-sponsor for medications (adjusted odds ratio = 0.21 (95% confidence interval: 0.12-0.38)) were significantly associated with good adherence The level of medication adherence to topical glaucoma medications is not good enough as compared to other studies done in Ethiopia. Male sex, urban residence, normal, and low visual acuity were positive predictors, whereas self-sponsored for medications was negative predictors for good adherence to glaucoma medications.
  • ||||||||||  Preclinical, Journal:  A Model of Glaucoma Induced by Circumlimbal Suture in Rats and Mice. (Pubmed Central) -  Apr 5, 2019   
    Staining of flat-mounted mouse retinae with a ganglion cell specific marker (RBPMS) confirmed ganglion cell loss. The circumlimbal suture is a simple, minimally invasive and cost-effective way to induce ocular hypertension that leads to ganglion cell injury in both rats and mice.
  • ||||||||||  Journal:  Brimonidine tartrate for the treatment of glaucoma. (Pubmed Central) -  Apr 5, 2019   
    Expert opinion: Despite clinical familiarity with brimonidine after two decades of use, agents that offer daily dosing, nocturnal effect, and more favorable ocular and systemic side effect profiles have ultimately led to brimonidine's adjunctive use in patients with elevated intraocular pressure or high- or low-tension glaucomas. Still, brimonidine may be advantageous in patients undergoing laser trabeculoplasty or iridotomy, in certain forms of glaucoma, or in pregnant individuals prior to the last trimester, underscoring its clinical importance.
  • ||||||||||  Journal:  XEN Implant for Glaucoma Treatment: A Review of the Literature. (Pubmed Central) -  Apr 5, 2019   
    Phacoemulsification is equally effective in terms of intraocular pressure control and visual outcome as phacotrabeculectomy with better safety and less post-operative complication. XEN implant devices have been developed as a surgical alternative for glaucomatous patients and are expected to play an important role in the management of glaucoma in the future.
  • ||||||||||  Review, Journal:  Glaucoma: Current treatment and impact of advanced drug delivery systems. (Pubmed Central) -  Apr 5, 2019   
    To overcome these drawbacks the novel drug delivery systems like In-situ gels, liposomes, niosomes, hydrogel, dendrimers, nanoparticles, solid lipid nanoparticles, Microneedles or ocular inserts play an important role to enhance the therapeutic efficacy of the anti-glaucomic drugs. The present review briefs the current treatments in terms of drugs used and in detail the impact of utilizing the above mentioned novel drug delivery systems in the treatment of glaucoma.
  • ||||||||||  Journal:  Sequence variation at ANAPC1 accounts for 24% of the variability in corneal endothelial cell density. (Pubmed Central) -  Apr 5, 2019   
    Most notably, an intergenic variant close to ANAPC1 (rs78658973[A], frequency = 28.3%) strongly associates with decreased cell density and accounts for 24% of the population variance in cell density (β = -0.77 SD, P = 1.8 × 10) and associates with increased CH (β = 0.19 SD, P = 2.6 × 10) without affecting risk of corneal diseases and glaucoma. Our findings indicate that despite correlations between cell density and eye diseases, low cell density does not increase the risk of disease.
  • ||||||||||  Journal:  Liver dysfunction for 8 years with hypertension for 1 week in an 8-year-old girl (Pubmed Central) -  Apr 5, 2019   
    The rare disease Alagille syndrome should be considered when a child has refractory hypertension with the involvement of multiple systems, especially liver dysfunction with cholestasis as the main manifestation. Genetic causes should be analyzed for a early diagnosis.
  • ||||||||||  5-fluorouracil / Generic mfg.
    New P4 trial, Surgery:  Efficacy and Safety of XEN (clinicaltrials.gov) -  Apr 5, 2019   
    P4,  N=100, Recruiting, 
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen
    Journal:  Era of steroid sparing in the management of immune-mediated inflammatory diseases. (Pubmed Central) -  Apr 4, 2019   
    Recently, new therapeutic strategies have been developed to reduce the dose or even eliminate the need for GCs; multi-target drug therapies for systemic lupus erythematosus (SLE), biological agents such as tocilizumab and rituximab for systemic vasculitis, and anakinra and tocilizumab for adult-onset still's disease. Therefore, the era of GC-sparing or GC-free treatment for IMIDs is on the horizon.